Definition

What Is Liver Cancer?

Primary liver cancer arises from cells within the liver. The dominant form (~80-90%¹) is hepatocellular carcinoma (HCC), arising from hepatocytes. Cholangiocarcinoma (~10-15%) arises from bile duct cells. The liver is also a common site for METASTATIC cancers from colon, breast, lung, and pancreas, these are not "liver cancer" but metastatic disease.

HCC almost always develops on a background of chronic liver disease, cirrhosis (any cause), chronic hepatitis B or C, NAFLD/NASH, hemochromatosis, or aflatoxin exposure. The risk in cirrhotic patients is ~2-5% per year. This is why HCC surveillance every 6 months in cirrhotics is non-negotiable, early detection is the only path to cure.

Globally, HCC is the 6th most common cancer and 3rd leading cause of cancer death. Geographic distribution reflects hepatitis B prevalence (high in Asia, Africa) and emerging NAFLD-related cases in Western countries. Universal HBV vaccination is the most powerful primary prevention.

⚠️ Surveillance Imperative: Every patient with cirrhosis or chronic HBV needs ultrasound + AFP every 6 months. Early HCC (Milan criteria⁴: single <5cm, or up to 3 lesions <3cm) is potentially curable via resection, ablation, or transplant. Late HCC is mostly palliative.

BCLC Staging

🌱 Very Early / Early (0-A)

Single tumor <2cm, OR up to 3 tumors <3cm. Preserved liver function (Child-Pugh A). Curative options: surgical resection, ablation, transplant. 5-year survival 50-70%.

🌗 Intermediate (B)

Multinodular, no vascular invasion, preserved function. Transarterial chemoembolization (TACE) standard. Median survival ~2-3 years with treatment.

🌑 Advanced / Terminal (C-D)

Vascular invasion, metastases, or severe symptoms. Systemic therapy (atezolizumab + bevacizumab; lenvatinib; sorafenib). Terminal stage: best supportive care.

Signs & Symptoms

Symptoms of Liver Cancer

Early HCC is usually asymptomatic, found only by surveillance imaging in cirrhotics. Once symptoms develop, disease is typically advanced.

🔍 Local / Hepatic Symptoms

😣

RUQ Pain / Discomfort

Dull aching in right upper quadrant. May radiate to right shoulder. Caused by liver capsule stretching as tumor grows. Sometimes sudden severe pain if tumor ruptures.

🟡

Jaundice (Late Sign)

Yellow eyes/skin, dark urine, pale stools. May indicate biliary obstruction by tumor, or progression of underlying cirrhosis.

🎈

Worsening Ascites (in Cirrhotics)

Rapid increase in abdominal fluid in previously stable cirrhotic patient. May indicate HCC growth, portal vein thrombosis from tumor.

📈

Hepatomegaly (Enlarged Liver)

Palpable liver mass on examination. Sometimes patient feels a "knot" in upper right abdomen. May be the first physical finding.

⚠️ Systemic & Paraneoplastic

⚖️

Weight Loss & Cachexia

Significant unintentional weight loss. Muscle wasting (sarcopenia). Loss of appetite. Often advanced disease.

😴

Profound Fatigue & Weakness

Disproportionate to activity. May be the dominant symptom. Combined with weight loss, suggests advanced disease.

🌡️

Low-Grade Fevers (Paraneoplastic)

Recurrent low-grade fevers without infection. Tumor cytokines. Sometimes the presenting feature.

🩸

Hypoglycemia / Erythrocytosis

Tumors may secrete insulin-like factors (hypoglycemia) or erythropoietin (high red cell count). Paraneoplastic syndromes diagnostic clue.

Diagnosis

How Liver Cancer Is Diagnosed

🩻 Surveillance & Imaging

📡 Surveillance Ultrasound + AFP

Every 6 months in cirrhotics or chronic HBV². AFP >20 ng/mL warrants further workup. Early detection is the only path to cure.

📡 Multiphasic CT or MRI

Liver-specific protocols with arterial, portal, delayed phases. Classic HCC: arterial hyperenhancement + washout. LI-RADS scoring system.

📡 Liver MRI with Eovist/Primovist

Hepatocyte-specific contrast, highest sensitivity for small HCCs. Used when CT findings unclear.

🔬 Biopsy (Sometimes)

In cirrhotic patients, imaging features often diagnose without biopsy. Biopsy reserved for atypical features, non-cirrhotic livers, or to guide systemic therapy.

🩸 Lab & Staging Workup

🩸 AFP, AFP-L3, DCP (PIVKA-II)

AFP not perfect (some HCCs don't secrete). AFP-L3 isoform and des-gamma-carboxy prothrombin (DCP) improve specificity.

🩸 Liver Function (Child-Pugh, MELD)

Albumin, INR, bilirubin, ascites, encephalopathy. Determines treatment eligibility, many HCC patients limited by underlying liver function.

📡 Staging (Extrahepatic Spread)

Chest CT (lung mets), bone scan if symptoms. Portal vein patency on imaging. PET-CT has limited role in HCC (variable uptake).

🩸 Etiology Workup

If newly diagnosed: HBV/HCV serologies, iron studies (hemochromatosis), AMA (PBC), autoimmune markers, alpha-1 antitrypsin. Treat underlying cause.

Treatment Comparison

Holistic vs. Conventional Treatment

🌿 HOLISTIC

💊 CONVENTIONAL

🌿

Holistic / Integrative Approach

PREVENTION (treat underlying liver disease) + SUPPORTIVE during conventional treatment

Primary Prevention

Address underlying liver disease: cure HCV, suppress HBV, eliminate alcohol, reverse NAFLD

Secondary Prevention

After curative treatment, coffee, statins (if eligible), HBV/HCV control reduce recurrence

During Treatment

Nutritional support; preserve liver function; minimize hepatotoxins

Caution

Many herbs and supplements are HEPATOTOXIC⁸, discuss EVERY supplement with hepatologist

Comprehensive Prevention & Support

Address underlying liver disease: cure HCV with DAAs, suppress HBV with antivirals, complete alcohol abstinence, reverse NAFLD with weight loss
Universal HBV vaccination, most powerful primary prevention worldwide
HCC surveillance every 6 months in cirrhotics and chronic HBV, non-negotiable
Coffee 2-3+ cups/day, most evidence-based dietary intervention; associated with roughly 40% lower HCC risk in meta-analyses of the general population³
Mediterranean diet, vegetables, fruits, olive oil, fish
Adequate protein (1.2-1.5g/kg), prevent sarcopenia, which worsens outcomes
Vitamin D optimization, deficient in most cirrhotic patients
Statin therapy if indicated, emerging evidence statins reduce HCC risk in cirrhotics
Address obesity, increases HCC risk independent of cause
Avoid hepatotoxic supplements, green tea extract (high-dose), kava, comfrey, chaparral, germander, pennyroyal. Even some "liver detox" supplements harm.
Avoid acetaminophen excess, limit <2g/day in chronic liver disease⁶
Avoid raw shellfish, Vibrio vulnificus fatal in cirrhotic patients
Minimize aflatoxin exposure, properly stored grains and nuts; avoid moldy peanuts/corn
Liver transplant evaluation if eligible, definitive treatment for early HCC + cirrhosis

✅ Critical Insight: Many "liver-supportive" herbs are actually hepatotoxic. Green tea EXTRACT (not tea) at high doses, kava, chaparral, comfrey, pennyroyal, germander, and various "liver cleanse" products have caused fulminant liver failure. Discuss EVERY supplement with your hepatologist.

💊

Conventional / Hepatology Approach

Stage-stratified: resection, ablation, transplant, TACE, systemic therapy

Very Early / Early

Surgical resection, radiofrequency/microwave ablation, OR liver transplant (Milan criteria)

Intermediate

TACE (transarterial chemoembolization), TARE (radioembolization with Y-90)

Advanced (Systemic)

Atezolizumab + bevacizumab (1st line), durvalumab + tremelimumab, lenvatinib, sorafenib

Second-Line

Regorafenib, cabozantinib, ramucirumab, nivolumab, pembrolizumab

Stage-Stratified Treatment

Surgical resection: for solitary tumors in non-cirrhotic livers or Child-Pugh A cirrhosis with preserved function. ~50-70% 5-year survival when resectable.
Ablation (RFA, MWA): for early-stage small tumors (<3cm). Comparable to surgery for very small lesions.
Liver transplantation: GOLD STANDARD for early HCC + cirrhosis meeting Milan criteria. Treats both the cancer AND underlying cirrhosis. ~70% 5-year survival.
TACE (Transarterial Chemoembolization): for intermediate-stage. Delivers chemotherapy directly to tumor via hepatic artery + embolization. Repeatable.
TARE / Y-90 Radioembolization: alternative to TACE; especially for portal vein thrombosis. Selective Internal Radiation Therapy.
Atezolizumab + bevacizumab: first-line for advanced HCC. IMbrave150 trial⁵, superior to sorafenib.
Durvalumab + tremelimumab (STRIDE): dual immunotherapy alternative first-line
Lenvatinib: first-line non-immunotherapy option; especially if bevacizumab contraindicated
Sorafenib: historical first-line; now usually second-line
Regorafenib, cabozantinib, ramucirumab: second-line options after sorafenib
Pembrolizumab, nivolumab: immunotherapy options for selected patients
Treat underlying liver disease aggressively: HCV cure, HBV suppression, alcohol abstinence, improves outcomes after cancer treatment

⚠️ Key Insight: Liver transplant is the only treatment that addresses BOTH the cancer and underlying cirrhosis simultaneously. For eligible patients with early HCC + advanced cirrhosis, transplant is often the best option. MELD exception points may prioritize HCC patients on the waiting list.

Nutritional Strategy

Diet for Liver Cancer & Prevention

Mediterranean diet + coffee + adequate protein + ZERO alcohol. Same principles as cirrhosis/NAFLD/viral hepatitis with added cancer-specific considerations.

✅ Prioritize:

☕ Coffee (2-3+ cups/day)

Meta-analyses associate any coffee intake with roughly 40% lower HCC risk, and each additional two cups a day with a further reduction. The best-evidenced dietary association for liver cancer, though the studies are observational and are not specific to people who already have cirrhosis. Both regular and decaf.³

🥚 High Protein (1.2-1.5g/kg)

Sarcopenia is the strongest modifiable predictor of mortality in liver disease. Eggs, fish, poultry, legumes, dairy.

🥦 Cruciferous & Allium

Broccoli, cauliflower, kale, garlic, onions. Sulforaphane induces Phase II enzymes. May reduce HCC risk.

🐟 Fatty Fish (2-3x/week)

Wild salmon, sardines. Omega-3 reduces hepatic inflammation, supports muscle preservation.

🌙 Late-Night Snack

Cirrhotic patients: bedtime carb+protein snack prevents overnight muscle catabolism. Yogurt with berries, cottage cheese.

❌ Strictly Avoid:

🚫 ALL Alcohol

Even small amounts accelerate cirrhosis and HCC risk. Complete abstinence required. No safe amount in liver disease.

🥜 Aflatoxin-Contaminated Foods

Properly store grains, nuts, corn. Discard moldy peanuts/corn. Aflatoxin B1 is potent liver carcinogen, especially synergistic with HBV.

🍣 Raw Shellfish

Vibrio vulnificus infection (from raw oysters) potentially fatal in cirrhotic patients. AVOID absolutely.

🍬 Refined Sugar & Fructose

Drives hepatic steatosis. Worsens NAFLD-related HCC risk. Eliminate sodas, sweets, HFCS.

💊 Hepatotoxic Supplements

High-dose green tea extract, kava, comfrey, chaparral, germander, pennyroyal, and many "liver cleanses." Show every supplement to your hepatologist.

Supplement Protocol

Evidence-Based Supplements

CAUTION: Liver cancer + cirrhosis = highest-risk patient for hepatotoxic supplements. Discuss every supplement with hepatologist. Below: relatively safer options with evidence.

Supplement	Mechanism & Evidence	Suggested Dose	Timing	Notes
Vitamin D3	Deficiency near-universal in cirrhosis; associated with worse HCC outcomes.	Test 25-OH-D first and set the dose with your clinician (titrate to 40 to 60 ng/mL, the Endocrine Society's preferred range)	With fat meal	Test baseline. Pair with K2 200mcg.
Omega-3 (EPA/DHA)	Anti-inflammatory; reduces hepatic inflammation. May slow HCC progression in lab studies.	2,000-3,000mg EPA+DHA/day	With fat meal	CAUTION with bleeding risk or before procedures.
BCAAs (Branched-Chain Amino Acids)	Best-studied supplement in cirrhosis. Supports muscle. May reduce HCC recurrence after curative treatment.	12-15g/day divided	Between meals + bedtime	Particularly helpful for sarcopenia. Evidence specifically in HCC survivors.
Milk Thistle (Silymarin)	Hepatoprotective in lab studies. Modest evidence in cirrhosis. Generally safe.	600-900mg/day standardized	Divided with meals	Choose phosphatidylcholine-bound forms.
Curcumin (Bioavailable)	Anti-inflammatory, anti-cancer effects in lab studies. Generally safe in cirrhotic patients.	500-1,500mg/day (phytosome or liposomal form)	With fat meal	Discuss timing around systemic therapy.
Selenium	Antioxidant cofactor; deficient in cirrhosis. Modestly may reduce HCC risk.	100-200mcg/day	With food	Don't exceed 400mcg long-term⁷.
Coffee (Food, Not Supplement)	2-3+ cups/day, associated with roughly 40% lower HCC risk. Proposed mechanisms: anti-inflammatory, reduced hepatic stellate cell activation.³	2-3+ cups/day	Throughout day	Most evidence-based dietary intervention.
Vitamin K	Reduced synthesis in liver disease. May have direct anti-tumor effect in HCC (lab evidence).	1-10mg/day (K2 MK-7 form)	With fat meal	Adjust dose with anticoagulants under physician supervision.

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed 27 August 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.⁹ Read this first, and read the second half of it twice. Nothing on this page treats liver cancer. The nutrition here supports liver function and general nutritional status around treatment; it is not an alternative to resection, ablation, transplant, embolization or systemic therapy, and no dietary change should delay treatment decided with your hepatology and oncology team. And this page carries a risk the others do not: the liver is the organ that metabolizes what you swallow, so MANY herbs and supplements are hepatotoxic, including several sold specifically for liver health. In established liver disease the margin for error is small. Clear every single supplement with your hepatologist before taking it, including anything on this page. The highest-value interventions for liver cancer are not supplements at all: treating hepatitis C, suppressing hepatitis B, stopping alcohol, and six-monthly surveillance if you have cirrhosis.

SEER (National Cancer Institute) liver and intrahepatic bile duct cancer statistics, and GLOBOCAN/IARC for global figures. seer.cancer.gov. Source for the histology split, with hepatocellular carcinoma accounting for roughly 80 to 90% of primary liver cancer and cholangiocarcinoma most of the remainder. ↩
On surveillance: AASLD guidance recommends ultrasound with or without alpha-fetoprotein every six months for adults with cirrhosis, and AFP above 20 ng/mL warrants further evaluation. aasld.org. Surveillance is the reason early, curable HCC is found at all, which is why the page states that early detection is the only path to cure. ↩
On coffee: Bravi F, et al. Coffee reduces risk for hepatocellular carcinoma, an updated meta-analysis. Clin Gastroenterol Hepatol. 2013, cghjournal.org, 16 studies and 3,153 cases, roughly 40% lower HCC risk for any coffee consumption against none; and later meta-analyses reporting about 35 to 43% lower risk per additional two cups a day, PubMed 32830818. These are observational, general-population figures. They are not specific to people who already have cirrhosis, and people who drink coffee differ from those who do not in ways cohorts cannot fully adjust for. Coffee is worth having; it is not a treatment. ↩
Milan criteria for liver transplantation in HCC (single tumour up to 5 cm, or up to three tumours each up to 3 cm, without vascular invasion or extrahepatic spread), and the resection and transplant survival figures quoted on this page. Transplant treats the cancer and the underlying cirrhosis together, which is why it is described as the reference standard for early HCC with cirrhosis. ↩
IMbrave150: Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. Source for atezolizumab plus bevacizumab as first-line therapy, having shown superior overall and progression-free survival against sorafenib. That comparison is between two drug regimens, not between a supplement and a drug. ↩
On acetaminophen in chronic liver disease: the commonly advised ceiling is 2 g/day rather than the usual 4 g, and it should be agreed with the treating team. Acetaminophen is not contraindicated in liver disease and is generally preferred to NSAIDs: a review of analgesics in chronic liver disease calls it the safest option at standard doses and advises avoiding NSAIDs, which carry bleeding and renal risks in cirrhosis and hepatotoxic potential of their own, PubMed 40904659. ↩
On selenium: the adult tolerable upper intake level is 400 mcg/day, which is the basis for the ceiling given on this page. ↩
On hepatotoxicity of supplements: LiverTox (NIH). LiverTox, NCBI Bookshelf. Herbal and dietary supplements are a leading identified cause of drug-induced liver injury in US registries, and the list includes products marketed for liver support. This is the reason for the warning at the top of this section. ↩
National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic.